A portfolio built at the intersection of science, clinical need and execution.
Logos Bioscience develops specialized ventures rather than forcing unrelated technologies into a single operating company. Each program has its own scientific thesis, development pathway, governance and economic architecture.
A biomedical strategy and business structuring platform for regulated innovation. Axiom integrates scientific strategy, regulatory intelligence, CMC/quality architecture and commercial structuring to originate and scale health ventures.
Axiom Biostrategy operates as the strategic core of the Logos ecosystem — providing the analytical, regulatory and business-architecture capabilities that allow each venture to be built with rigor from day one.
Axiom Biostrategy is a strategic platform within the Logos Bioscience ecosystem. It does not constitute a consulting firm, CRO, CDMO or clinical service provider.
CAR-T México
A localized advanced-cell-therapy platform designed to expand the development and future accessibility of CD19 CAR-T through international technology transfer, regulated manufacturing and structured clinical development in Mexico.
CAR-T México brings together technology, manufacturing, quality, clinical and regulatory capabilities within a coordinated development model. The venture is being structured to establish a scientifically rigorous and economically sustainable pathway for advanced cell therapy in Mexico.
This program is in development. Information on this website does not constitute an offer of medical treatment or a representation of regulatory approval.
CellBilden
A longevity and life-optimization platform built on an integrated chain of biological evaluation, screening, potentiation and longitudinal follow-up.
CellBilden explores how biological screening, inflammatory profiles, cellular-function measurements and longitudinal data can support more structured and individualized health strategies.
This platform is in development. It does not constitute a diagnostic service, approved medical device or clinical offering.
SpineForce
A development platform focused on minimally invasive regenerative solutions for intervertebral degeneration and spinal conditions.
SpineForce is being structured around regenerative, injectable and minimally invasive approaches to spinal health. Additional information is available through confidential strategic discussions.
This program is in early-stage development. No specific mechanism, indication or performance claims are represented.
MyoPatch
A development platform based on biological matrix for myocardial repair and cardiovascular regenerative support.
MyoPatch is being structured around decellularized extracellular matrix (dECM), tissue support and cellular adhesion approaches for cardiovascular applications. Additional information is available through confidential strategic discussions.
This program is in early-stage development. No specific mechanism, indication or performance claims are represented.
Some opportunities require discretion before visibility.
Logos Bioscience also evaluates and develops confidential technologies that are not publicly disclosed. Technology owners, institutions and investors may contact us directly to discuss qualified opportunities under an appropriate confidentiality framework.
Submit a Confidential Opportunity